Knight Therapeutics Inc. updated revenue guidance for fiscal 2022. For the year company has updated its guidance and expects to generate $265 to $275 million in revenue, an increase of $5 million on the lower and upper range.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
5.83 CAD | -0.68% | +0.69% | +12.33% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.33% | 434M | |
+19.29% | 80.67B | |
+13.63% | 9.17B | |
-15.14% | 4.86B | |
+46.88% | 4.55B | |
+15.70% | 4.34B | |
+10.89% | 2.38B | |
-27.88% | 2.2B | |
+15.73% | 2.1B | |
-43.02% | 1.86B |
- Stock Market
- Equities
- GUD Stock
- News Knight Therapeutics Inc.
- Knight Therapeutics Inc. Updates Revenue Guidance for Fiscal 2022